SPX Technologies (SPXC) investor relations material

Business overview and market positioning

• Operates in HVAC and Detection & Measurement, with 70% of business in HVAC and 29% in Detection & Measurement, primarily in the Americas.

• Holds leading positions in engineered niches, focusing on tech-enabled, custom-configured equipment for diverse applications including data centers, healthcare, and commercial buildings.

• Maintains strong trade brands, with most revenue from products where it is the market leader or second in the market.

• Achieved significant EBITDA growth, nearly doubling from $310M to $613M in three years, ahead of its four-to-five-year target.

• High cash conversion rate, generating 95–100% of net income as cash.

Growth strategy and operational initiatives

• Growth driven by digital and AI integration, Lean manufacturing, talent development, new product launches, and commercial excellence.

• Strategic M&A is central, with $2.5B deployed over 7–8 years, focusing on proprietary deals and accretive acquisitions in the $50M–$500M range.

• Maintains a pipeline of over 300 M&A targets, with half of acquisitions being proprietary.

• Recent acquisitions have accelerated growth in engineered air movement, electric heat, and CommTech, with several businesses doubling or tripling post-acquisition.

• No regular dividends; capital deployment is focused on growth and select share buybacks during market dislocations.

Segment performance and end-market trends

• HVAC segment sees strong growth from data centers, with organic growth rates well above the 5–6% medium-term target.

• Detection & Measurement segment is global, with two-thirds of revenue from the Americas and significant presence in Europe and Asia.

• Data center revenue guidance raised from $300M to $350M for the year, with capacity expanding from $200M to $750M through new facilities.

• OlympusVMAX, a new data center product, exceeded booking and revenue targets, with further growth expected as new facilities come online.

• Healthcare, pharma, and drug delivery markets also show strong growth, with healthy win rates and robust demand.